Dyadic International Inc. (NASDAQ:DYAI) Short Interest Down 76.2% in June

Dyadic International Inc. (NASDAQ:DYAI) saw a large decrease in short interest in June. As of June 15th, there was short interest totaling 148,312 shares, a decrease of 76.2% from the May 31st total of 622,465 shares. Based on an average trading volume of 188,919 shares, the short-interest ratio is currently 0.8 days. Currently, 0.5% of the company’s stock are sold short.

Institutional Investors Weigh In On Dyadic International

A number of hedge funds have recently bought and sold shares of DYAI. Bank of America Corp DE grew its holdings in Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 26,965 shares in the last quarter. Marathon Capital Management purchased a new position in shares of Dyadic International during the third quarter worth approximately $41,000. Geode Capital Management LLC boosted its stake in shares of Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after buying an additional 36,266 shares during the period. Landscape Capital Management L.L.C. acquired a new stake in shares of Dyadic International during the third quarter worth $190,000. Finally, Apis Capital Advisors LLC acquired a new stake in Dyadic International in the third quarter valued at about $1,817,000. Institutional investors and hedge funds own 27.95% of the company’s stock.

Dyadic International Price Performance

DYAI stock traded up $0.08 during mid-day trading on Monday, reaching $0.88. The company’s stock had a trading volume of 122,277 shares, compared to its average volume of 165,241. The company has a current ratio of 2.42, a quick ratio of 2.42 and a debt-to-equity ratio of 4.08. The company’s 50 day moving average is $0.76 and its two-hundred day moving average is $0.83. Dyadic International has a fifty-two week low of $0.65 and a fifty-two week high of $1.35. The stock has a market cap of $32.07 million, a PE ratio of -3.83 and a beta of 1.17.

Dyadic International (NASDAQ:DYAI) last posted its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The firm had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $0.90 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. Equities research analysts expect that Dyadic International will post 0.13 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research note on Wednesday. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $3.00.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.